Inebilizumab 是一种抗CD19单克隆抗体 (mAb)，对 B 细胞具有增强的抗体依赖细胞介导的细胞毒性。 Inebilizumab 可用于多发性硬化和视神经脊髓炎的研究。
| 生物活性 | Inebilizumab is an anti-CD19monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research[1]. |
体外研究
(In Vitro) | Inebilizumab is derived from the mouse anti-human mAb HB12b, which had already shown impressive activity in depletion of B cells in transgenic mice carrying the human CD19 gene (hCD19 Tg)[1].
Inebilizumab potently depletes CD19-expressing B cells, including primary human B cells, B cell lines derived from multiple tumor types, and neoplastic B cells[1].
Inebilizumab demonstrates equal or better activity than Rituximab (HY-P9913) in depletion of human primary B cells in autologous ADCC assays and shows potent ADCC activity against human in vitro-differentiated and primary plasma cells[1].
|
体内研究
(In Vivo) | Inebilizumab (MEDI-551) (0-10 mg/kg; i.v.; once) depletes B cells from blood and spleen by mouse macrophages in vivo and phagocytosis of murine B cells ex vivo[2].
| Animal Model: | huCD19/CD20 double Tg mice[2] | | Dosage: | 0.5, 2, or 10 mg/kg | | Administration: | Tail vein injection, once | | Result: | Depleted B cells from blood and spleen, B-cell depletion in blood and spleen was maintained for more than 2 weeks after a single 10 mg/kg administration (better than Rituximab). Resulted in a substantial reduction (on average by 91.4% by day 3) in BM B220+muCD19+ B cells. Led to depletion of B cell by mouse macrophages. |
|
| Clinical Trial | |
| CAS 号 | |
| 中文名称 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com